Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment. Check your account now to learn when your revalidation is due. More information here.

Drugs and Therapeutics (D & T) Committee Meeting Results for: March 20, 2013

Drug Name	Review Type	Committee Recommendation	Prior Approval Status � Final Determination
Quillivant XR	New Drug Initial Review	Require Prior Approval	Prior Approval Required
Xeljanz	New Drug Initial Review	Require Prior Approval	Prior Approval Required
Aubagio	New Drug Initial Review	Require Prior Approval	Prior Approval Required
Eliquis	New Drug Initial Review	Require Prior Approval	Prior Approval Required
Sklice	New Drug Initial Review	Require Prior Approval	Prior Approval Required
Gattex	New Drug Initial Review	Require Prior Approval	Prior Approval Required
Oxtellar XR	New Drug Initial Review	Require Prior Approval	Prior Approval Required
Tudzorza Pressair	New Drug Initial Review	Require Prior Approval	Prior Approval Required
Natroba	New Drug Appeal	Require Prior Approval	Prior Approval Required
Brilinta	PDL Appeal	Require Prior Approval	Prior Approval Required
Latuda	PDL Appeal	Remove Prior Approval Requirement	Prior Approval Requirement Removed

Footer